Patents by Inventor Jonathan Stuart Foot
Jonathan Stuart Foot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230349907Abstract: The present invention relates to novel bioprobes which are capable of binding to certain amine oxidase enzymes. These bioprobes are useful in methods of detecting and determining the concentration of certain amine oxidase enzymes in a sample as well as in methods for the quantitative assessment of inhibition of certain amine oxidases.Type: ApplicationFiled: February 5, 2021Publication date: November 2, 2023Applicant: Pharmaxis Ltd.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Heidi Schilter Sambade, Wenbin Zhou, Lara Anne Perryman
-
Publication number: 20230257342Abstract: The present invention relates to novel compounds which are capable of inhibiting semicarbazide-sensitive amine oxidase (SSAO/VAP-1) and monoamine oxidase B (MAO-B). These compounds are useful for treatment of a variety of neuromuscular diseases, such as muscular dystrophies, and neuroinflammatory diseases, including both peripheral and central disorders in human subjects, as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: ApplicationFiled: June 25, 2021Publication date: August 17, 2023Inventors: Alan Duncan Robertson, Alison Dorothy Findlay, Alberto Buson, Craig Ivan Turner, Dieter Wolfgang Hamprecht, Jonathan Stuart Foot, Mandar Deodhar, Wolfgang Jarolimek, Serena Becchi, Bernard Walter Balleine, Marcella Canton, Libero Vitiello, Bert Blaauw
-
Publication number: 20210353571Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: ApplicationFiled: August 2, 2019Publication date: November 18, 2021Inventors: Alison Dorothy FINDLAY, Craig Ivan TURNER, Mandar DEODHAR, Jonathan Stuart FOOT, Wolfgang JAROLIMEK, Wenbin ZHOU, Alberto BUSON, Angelique Elsa GRECO
-
Patent number: 11098045Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: GrantFiled: June 11, 2020Date of Patent: August 24, 2021Assignee: Pharmaxis Ltd.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Publication number: 20200317666Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: ApplicationFiled: June 11, 2020Publication date: October 8, 2020Applicant: PHARMAXIS LTD.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Patent number: 10717733Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: GrantFiled: February 10, 2017Date of Patent: July 21, 2020Assignee: Pharmaxis Ltd.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Patent number: 10717734Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: GrantFiled: February 10, 2017Date of Patent: July 21, 2020Assignee: Pharmaxis Ltd.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Publication number: 20200069648Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: ApplicationFiled: March 2, 2018Publication date: March 5, 2020Inventors: Alison Dorothy FINDLAY, Craig Ivan TURNER, Mandar DEODHAR, Jonathan Stuart FOOT, Wenbin ZHOU, Wolfgang JAROLIMEK, Alan Duncan ROBERTSON
-
Publication number: 20190119269Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: ApplicationFiled: February 10, 2017Publication date: April 25, 2019Applicant: PHARMAXIS LTD.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Publication number: 20190071396Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.Type: ApplicationFiled: November 1, 2018Publication date: March 7, 2019Inventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
-
Publication number: 20190040007Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: ApplicationFiled: February 10, 2017Publication date: February 7, 2019Applicant: PHARMAXIS LTD.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Patent number: 10160723Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.Type: GrantFiled: October 5, 2017Date of Patent: December 25, 2018Assignee: Boehringer Ingelheim International GmbHInventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
-
Publication number: 20180086698Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.Type: ApplicationFiled: October 5, 2017Publication date: March 29, 2018Inventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
-
Patent number: 9815782Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.Type: GrantFiled: February 26, 2016Date of Patent: November 14, 2017Assignee: Boehringer Ingelheim International GmbHInventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
-
Publication number: 20160244406Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.Type: ApplicationFiled: February 26, 2016Publication date: August 25, 2016Applicant: Boehringer Ingelheim International GmbHInventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
-
Patent number: 9302986Abstract: The preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I: is described. Methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer, are also described.Type: GrantFiled: April 5, 2013Date of Patent: April 5, 2016Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
-
Publication number: 20150158813Abstract: The preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I: is described. Methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer, are also described.Type: ApplicationFiled: April 5, 2013Publication date: June 11, 2015Inventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan D. Robertson, Craig Ivan Turner
-
Patent number: 8426587Abstract: The present invention is related to the preparation and pharmaceutical use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: (I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.Type: GrantFiled: November 19, 2008Date of Patent: April 23, 2013Assignee: Pharmaxis Ltd.Inventors: Ian A. McDonald, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot
-
Publication number: 20100298330Abstract: The present invention is related to the preparation and pharmaceutical In use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification:(I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.Type: ApplicationFiled: November 19, 2008Publication date: November 25, 2010Applicant: PHARMAXIS LTD.Inventors: Ian A. McDonald, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot